Up­dat­ed: Bio­gen sells just $300K worth of Aduhelm in Q3, as ques­tions on long-term vi­a­bil­i­ty re­main

Bare­ly any­one is ac­cess­ing Bio­gen’s con­tro­ver­sial Alzheimer’s treat­ment, with the com­pa­ny re­port­ing just $0.3 mil­lion in Aduhelm sales in the third quar­ter. Al­though in­vestors will be look­ing to the longer term, when CMS may de­cide to cov­er the drug and open the flood­gates for more re­im­burse­ment, use of the drug is cur­rent­ly stalled.

Since June, when the FDA first signed off on the drug un­der its ac­cel­er­at­ed path­way, Bio­gen said Wednes­day that it’s sold a to­tal of $2 mil­lion worth of Aduhelm. That’s a far cry from the peak Wall Street sales es­ti­mate of about $9 bil­lion in an­nu­al sales, and even a ways away from the sell-side con­sen­sus of about $17 mil­lion in Q3 sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER